Have a feature idea you'd love to see implemented?
Let us know!
VNDA Vanda Pharmaceuticals Inc
Price (delayed)
$4.81
Market cap
$280.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$185.45M
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Highlights
VNDA's debt is down by 27% year-on-year and by 9% since the previous quarter
VNDA's gross margin is up by 2.1% YoY
VNDA's quick ratio is down by 23% YoY but it is up by 2.6% from the previous quarter
The revenue has decreased by 10% YoY but it has increased by 4.9% QoQ
VNDA's net income is down by 50% since the previous quarter
The company's EPS fell by 45% QoQ
Key stats
What are the main financial stats of VNDA
Market
Valuations
Earnings
Shares outstanding
58.31M
Market cap
$280.46M
Enterprise value
$185.45M
Price to book (P/B)
0.52
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
Revenue
$190.86M
Gross profit
$178.67M
Net income
-$16.39M
EBIT
-$18.09M
EBITDA
-$10.77M
Free cash flow
-$18.2M
Per share
Balance sheet
Liquidity
EPS
-$0.29
EPS diluted
-$0.29
Free cash flow per share
-$0.31
Book value per share
$9.29
Revenue per share
$3.28
TBVPS
$9.08
Total assets
$645.12M
Total liabilities
$103.89M
Debt
$5.49M
Equity
$541.22M
Working capital
$343.3M
Debt to equity
0.01
Current ratio
4.85
Quick ratio
4.7
Net debt/EBITDA
8.82
Margins
Efficiency
Dividend
EBITDA margin
-5.6%
Gross margin
93.6%
Net margin
-8.6%
Operating margin
-19.6%
Return on assets
-2.5%
Return on equity
-3%
Return on invested capital
-5.5%
Return on capital employed
-3.3%
Return on sales
-9.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNDA stock price
How has the Vanda Pharmaceuticals stock price performed over time
Intraday
-0.41%
1 week
3.89%
1 month
-3.41%
1 year
18.77%
YTD
13.98%
QTD
2.56%
Financial performance
How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$190.86M
Gross profit
$178.67M
Operating income
-$37.48M
Net income
-$16.39M
Gross margin
93.6%
Net margin
-8.6%
VNDA's net income is down by 50% since the previous quarter
VNDA's net margin is down by 43% since the previous quarter
The operating income has contracted by 15% from the previous quarter
The revenue has decreased by 10% YoY but it has increased by 4.9% QoQ
Growth
What is Vanda Pharmaceuticals's growth rate over time
Valuation
What is Vanda Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.52
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
The company's EPS fell by 45% QoQ
VNDA's P/B is 57% below its 5-year quarterly average of 1.2 but 4% above its last 4 quarters average of 0.5
VNDA's P/S is 39% below its 5-year quarterly average of 2.4 and 2% below its last 4 quarters average of 1.5
The revenue has decreased by 10% YoY but it has increased by 4.9% QoQ
Efficiency
How efficient is Vanda Pharmaceuticals business performance
Vanda Pharmaceuticals's ROIC has plunged by 53% from the previous quarter
Vanda Pharmaceuticals's return on equity has shrunk by 50% QoQ
Vanda Pharmaceuticals's ROA has decreased by 47% from the previous quarter
The company's return on sales fell by 44% QoQ
Dividends
What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNDA.
Financial health
How did Vanda Pharmaceuticals financials performed over time
VNDA's quick ratio is down by 23% YoY but it is up by 2.6% from the previous quarter
The current ratio is down by 23% year-on-year but it is up by 3.6% since the previous quarter
VNDA's debt is 99% smaller than its equity
VNDA's debt is down by 27% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.